A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Recruiting · NCT07317505 · Interventional (participants receive a specific treatment) · Lead sponsor: Conjupro Biotherapeutics, Inc.
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The goal of this clinical trial is to test JMT108, a type of drug called a bispecific antibody in adult patients with locally advanced or metastatic solid tumors. The main questions it aims to answer are: * To assess the safety and tolerability of JMT108 at increasing doses and determine the dose and schedule to be used in the second part of the study (Phase 1a) * To assess effectiveness of JMT108 in participants with locally advanced or metastatic tumors (Phase 1b) * To evaluate how quickly JMT108 is metabolized by the body (pharmacokinetics or PK) * To evaluate if antibodies to the study drug develop (immunogenicity) * To evaluate preliminary efficacy to the drug * To explore the pharmacodynamic (PD) characteristics of JMT108 * To explore the correlation between biomarker levels and preliminary efficacy Participants will: * Provide written informed consent * Undergo screening tests to ensure they are eligible for study treatment * Attend all required study visits and receive JMT108 by intravenous injection every 2 weeks until the study doctor determines study treatment should be stopped, based on how well a participant is doing on treatment * Be followed for progression every 3 months for up to 2 years
Who can take part
Inclusion criteria
- Age ≥18 years
- Participants with histologically or cytologically confirmed locally advanced or metastatic solid tumors who are unresponsive or intolerant to all standard of care or have no standard of care available
- At least one evaluable tumor lesion according to RECIST v1.1.
- ECOG performance status score ≤2.
- Expected survival ≥ 3 months
- Major
Exclusion criteria
- Active central nervous system metastases and/or leptomeningeal metastases
- AEs from prior therapy which have not recovered to Grade ≤1 or baseline as per NCI CTCAE v5.0
- Prior therapy
- Any other unapproved investigational drugs or treatments within 4 weeks prior to the first dose of the investigational drug (C1D1).
- Chemotherapy, radiotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy, or other anti-tumor therapies within 4 weeks prior to the first dose of the investigational drug, except in the following situations:
- Nitrosoureas or mitomycin C within 6 weeks prior to the first dose of the investigational drug;
- Use of oral fluoropyrimidines and small-molecule targeted drugs within 2 weeks or 5 half-lives of the drug (whichever is longer) prior to the first dose of the investigational drug;
- Use of herbal medicine/products with anti-tumor indications within 2 weeks prior to the first dose of the investigational drug.
Where it is running
6 locations listed across 3 US states.
- Carolina BioOncology Institute - Huntersville, North Carolina, United States
- Carolina BioOncology Institute - Huntersville, North Carolina, United States
- NEXT Dallas - Dallas, Texas, United States
- NEXT Dallas - Dallas, Texas, United States
- NEXT Virginia - Fairfax, Virginia, United States
- NEXT Virginia - Fairfax, Virginia, United States